WAVEMAN · COMPANY

CTKB · Cytek Biosciences, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

CTKB

Name: Cytek Biosciences, Inc. (CTKB) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Cytek Biosciences, Inc.

MEDICAL DEVICES · LABORATORY ANALYTICAL INSTRUMENTS · CIK 0001831915

FORM 144 · 1☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+0.5%

XBRL, annual

NET MARGIN

-33.0%

CONVERSIONS · 180D

codes C/M, not in net · no price filed

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

76 funds added or opened last quarter

more than 50% of Medical Devices

REVENUE

+0.5% year over year

below 73% of Medical Devices

MARGIN

-33.0% net margin

below 67% of Medical Devices

BUYBACKS

$80.8M repurchased, FY to 2025-12-31

more than 58% of Medical Devices

SHORT

3.8% of shares outstanding short · 7.5 days to cover · settled 2026-07-31

more than 53% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

76 funds added or opened positions in the latest 13F quarter, of 157 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +16.9%

+16.9%12M

FORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows 76 funds added last quarter, $146.5K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Cytek Biosciences, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

McCombe William D.

Chief Financial Officer

BUY

2025-06-02

35,000.0

$97.3K

Yan Ming

CHIEF TECHNOLOGY OFFICER

SELL

2024-04-19

20,000.0

$117.4K

Yan Ming

CHIEF TECHNOLOGY OFFICER

SELL

2024-04-09

400.0

$2.8K

Yan Ming

CHIEF TECHNOLOGY OFFICER

SELL

2024-04-09

1,500.0

$10.5K

Yan Ming

CHIEF TECHNOLOGY OFFICER

SELL

2024-03-19

20,000.0

$134.2K

102 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 97 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

9,578,643.0 sh

$42.4M

MILLENNIUM MANAGEMENT LLC

9,338,010.0 sh

$41.4M

Boston Partners

7,660,943.0 sh

$33.9M

HHLR ADVISORS, LTD.

6,657,030.0 sh

$29.5M

Topline Capital Management, LLC

6,283,450.0 sh

$27.8M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

PHILIPPE BUSQUE

FILED 2026-09-02

$146.5K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

WPG Partners Select Small Cap Value Fund

$3.1M POSITION · AS OF 2026-02-28

1.5%

Brown Capital Management Small Company Fund

$4.6M POSITION · AS OF 2026-03-31

1.4%

Royce Micro-Cap Fund

$2.1M POSITION · AS OF 2026-03-31

0.6%

Royce Capital Fund - Micro-Cap Portfolio

$660.8K POSITION · AS OF 2026-03-31

0.6%

Dunham Small Cap Value Fund

$541.8K POSITION · AS OF 2026-04-30

0.6%

Column Small Cap Select Fund

$7.8M POSITION · AS OF 2026-02-28

0.5%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Executive pay vs shareholder return · Wenbin Jiang, Ph.D

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2023

$4.9M

$3.7M

$2.0M

-51%

-14%

2022

$3.9M

$1.9M

$1.4M

-46%

-18%

2021

$4.8M

-$130.5K

$2.6M

-13%

-9%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$201.5M	$200.5M	$193.0M	$164.0M
GROSS PROFIT	$104.5M	$111.1M	$109.4M	$101.0M
OPERATING INCOME	$-40.4M	$-20.5M	$-27.8M	$-1.8M
NET INCOME	$-66.5M	$-6.0M	$-12.1M	$2.5M
EPS (DILUTED)	—	—	-0.09	0.02
OPERATING CASH FLOW	$-4.7M	$25.4M	$5.3M	$-12.2M
CASH	$90.9M	$98.7M	$167.3M	$296.6M
BUYBACKS	$15.1M	$21.6M	$44.2M	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE